Nintedanib Delays Progression of Advanced Ovarian Cancer
UBM Medica,
Women with chemotherapy-naive advanced ovarian cancer gained significant delays in the progression of their disease when they…
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Overview of attention for article published in Lancet Oncology, November 2015
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (94th percentile)
-
Good Attention Score compared to outputs of the same age and source (78th percentile)
Mentioned by
- news
- 1 news outlet
- policy
- 1 policy source
- 16 X users
- 3 Facebook pages
- guideline
- 3 clinical guideline sources
Readers on
- mendeley
- 236 Mendeley